Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following ...

Xentria announced a planned amendment to its XTMAB-16 clinical trial for pulmonary sarcoidosis following FDA feedback, proposing increased patient enrollment and an extended 52-week efficacy study. The trial will evaluate XTMAB-16 at 4mg/kg every four weeks, aiming to advance clinical development for this rare disease with no current FDA-approved anti-TNFα treatments.

This Wire brief sits within Fusion42's coverage of Biotech.